10A

Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older

Retrieved on: 
Tuesday, November 28, 2023
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, MSD, OPA, Safety, NYSE, Cohort, Merck & Co., Aes, Risk, Immunodeficiency, Patient, Molina Healthcare, GMT (TV programme), Vaccine, 9N, Fungal infection, Leucauge, Streptococcus, 20A, 10A, CDC, Attenuated vaccine, EST, Public, MRK, Pharmaceutical industry, PCV20, V116, Merck

The trial evaluated the immunogenicity, tolerability and safety of V116 compared to PCV20 (pneumococcal 20-valent conjugate vaccine) in adults who had not previously received a pneumococcal vaccine.

Key Points: 
  • The trial evaluated the immunogenicity, tolerability and safety of V116 compared to PCV20 (pneumococcal 20-valent conjugate vaccine) in adults who had not previously received a pneumococcal vaccine.
  • In adults 18 to 49 years of age (Cohort 2), V116 elicited non-inferior immune responses (immunobridged) compared to adults 50 to 64 years of age, as assessed by serotype-specific OPA GMTs 30 days post-vaccination.
  • If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults.
  • Participants administered V116 and PCV20 who reported at least 1 adverse event (AE) were 61.7% and 67.2%, respectively.

Khadas Introduces Mind Series to Deliver a Next-Gen Portable Computing Experience with an Innovative Ecosystem

Retrieved on: 
Thursday, August 24, 2023
10A, Communication, Data-rate units, Mini, Workflow, Friends, TB, Sleep, M.2, USB, PCI Express, Mind, Temperature, HDMI, USD, Sale, Kickstarter, SSD, UCI race classifications, Intel Core, A4, Dream, CPU, Restaurant, NVIDIA, RAM, Intel, AAC, Architecture, Paper, SD, Ecosystem, VC, GPU, Xplay, Video game, Cassette tape, Mobile phone

SHENZHEN, China, Aug. 24, 2023 /PRNewswire/ -- Khadas, an emerging technology company that designs and manufactures cutting-edge computing and electronic devices, today announces the launch of a Kickstarter crowdfunding campaign for their next-generation portable-computer series, the Khadas Mind Portable Workstation. The company is also developing a versatile ecosystem of peripherals for the Khadas Mind, that is based upon its proprietary Mind Link interface. 

Key Points: 
  • The company is also developing a versatile ecosystem of peripherals for the Khadas Mind, that is based upon its proprietary Mind Link interface.
  • This enables Khadas Mind to seamlessly integrate with other devices within the Khadas Mind ecosystem, including but not limited to the Mind Dock, Mind Graphics, Mind xPlay, and more.
  • The Mind Dock is a powerful docking station designed to expand the I/O capabilities of Khadas Mind.
  • When linked with Khadas Mind, Mind Dock supports up to four simultaneous 4K/60Hz displays, enabling a multi-screen visual experience.

Superdry plc: ROI-Result of Equity Issue

Retrieved on: 
Thursday, May 4, 2023
MAKE, 10A, Financial Conduct Authority, Person, II, LONDON, UNITED STATES, NO, 1997 Constitution of Fiji: Chapter 3, Investment, European Economic Area, Risk, Prejudice, Markets in Financial Instruments Directive 2014, Financial Services and Markets Act 2000, London Stock Exchange, FSMA, Relevance (Person of Interest), Trustee, SELL, Uncertainty, European Union (Withdrawal) Act 2018, ALL, Disclosure, Main Market, Onitsha, Finance, US, FCA, FORM, Fiscal policy, AFRICA, Financial services, Reproduction, Sale, Republic, Prospectus, London, Nature, ANY, AN, United Kingdom, Security (finance), Cryptocurrency, Liberum veto, Superdry, EU, Regulation

The distribution of this Announcement and the Equity Raise and/or the offer or sale of the New Ordinary Shares in certain jurisdictions may be restricted by law.

Key Points: 
  • The distribution of this Announcement and the Equity Raise and/or the offer or sale of the New Ordinary Shares in certain jurisdictions may be restricted by law.
  • This Announcement does not constitute a recommendation concerning any investor's options with respect to the Equity Raise.
  • The UK Target Market Assessment is without prejudice to any contractual, legal or regulatory selling restrictions in relation to the Equity Raise.
  • The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Equity Raise.

U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children

Retrieved on: 
Thursday, April 27, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Vaccine, ACIP, Pneumococcal conjugate vaccine, 10A, Inc., Streptococcus, Senior, Prevalence, Vaccination, IPD, Parent, PFE, Streptococcus pneumoniae, Research, Infection, Otitis media, CDC, Development, Texas Children's Hospital, Division, Peterborough, Baylor College of Medicine, PCV, Hospital, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, NYSE, Food, Disease, Pharmaceutical industry, Pfizer

“Today's FDA approval of our vaccine, PREVNAR 20, now offers parents the ability to help protect their children against 20 pneumococcal serotypes in circulation, which represent the majority of pneumococcal disease in U.S. infants and children,"1,2 said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer.

Key Points: 
  • “Today's FDA approval of our vaccine, PREVNAR 20, now offers parents the ability to help protect their children against 20 pneumococcal serotypes in circulation, which represent the majority of pneumococcal disease in U.S. infants and children,"1,2 said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer.
  • “This important PREVNAR 20 approval builds on more than 20 years of real-world impact with PREVNAR and PREVNAR 13, safety data, and effectiveness; highlighting Pfizer's leadership in developing groundbreaking pneumococcal conjugate vaccines to help protect infants and their families from life threatening infections.
  • "We are thrilled with this approval as it signifies a new chapter in pediatric pneumococcal conjugate vaccination.
  • Further positive data from a Proof-of-Concept Phase 2 study (NCT03512288) that assessed the safety and immunogenicity of PREVNAR 20 also supported the FDA’s decision.

ZimVie Announces Expanded Reimbursement and Exemplary Clinical Rating for Mobi-C®

Retrieved on: 
Monday, April 3, 2023
Systematic review, 10A, Surgeon, Health Insurance Fund, Physician, National Health Insurance Fund, Republic, Motion, Patient, JORF, Biomedical text mining, United Kingdom, National Institute for Health and Care Excellence, FDA, WHO model list of essential in vitro diagnostics, LPP, News, NICE, Medical device, Health

In addition, the clinical data for Mobi-C was awarded the highest quality rating of 10A* by the Orthopaedic Data Evaluation Panel in the United Kingdom.

Key Points: 
  • In addition, the clinical data for Mobi-C was awarded the highest quality rating of 10A* by the Orthopaedic Data Evaluation Panel in the United Kingdom.
  • “This reimbursement of the Mobi-C prosthesis is really excellent news.
  • ODEP provides the objective, systematic review and rating of the strength of evidence supporting the performance of medical devices.
  • “We applaud the French reimbursement decision for Mobi-C and welcome the exemplary 10A* rating from ODEP,” said Rebecca Whitney, Global President of ZimVie Spine.

Diodes Incorporated Releases Its First Silicon Carbide Schottky Barrier Diodes (SBD)

Retrieved on: 
Monday, January 30, 2023
Technology, Mobile, Wireless, Semiconductor, Automotive, General Automotive, Other Technology, Other Automotive, Hardware, Consumer Electronics, DC, AC-DC, Silicon carbide, VF, DC-DC, QC, Maintenance, 10A, SBD, DIOD, Electronics, Electric motor

Diodes Incorporated (Diodes) (Nasdaq: DIOD) today announced the release of its first Silicon Carbide (SiC) Schottky barrier diodes (SBD).

Key Points: 
  • Diodes Incorporated (Diodes) (Nasdaq: DIOD) today announced the release of its first Silicon Carbide (SiC) Schottky barrier diodes (SBD).
  • The portfolio includes the DIODES™ DSCxxA065 series with eleven products rated at 650V (4A, 6A, 8A, and 10A) and the DIODES™ DSCxx120 series with eight products rated at 1200V (2A, 5A, and 10A).
  • The devices are suitable for AC-DC, DC-DC, and DC-AC switching converters, photovoltaic inverters, uninterruptable power supplies, and industrial motor drive applications.
  • The DSCxxA065 and DSCxx120 series are available from $1.24 to $2.33 and $1.70 to $6.68 respectively in 1,000 piece quantities.

The automotive relay market is projected to grow from USD 12.2 billion in 2022 to USD 15.5 billion by 2027, at a CAGR of 5.0%

Retrieved on: 
Thursday, December 22, 2022
Power windows, Anti-lock braking system, Panasonic, Air conditioning, TE Connectivity, Fan, Power seat, Tesla, Battery electric vehicle, Traction control system, Research, Intelligent Parking Assist System, Hybrid (biology), Marketing, Denso, Omron, Door lock, Starter, Volkswagen, VPS, TCS, Protective relay, 10A, PCB, ABS, CXO, Economy, EPS, IPA, ICE, Electronics, TE, Organization, USD, Pulse, Fuel injection, EV, Lexus, Consultant, Hongfa Community, BMW, OEM, Sport utility vehicle, Tail, Rail transport, Communications satellite, Sunroof, Lighting

View original content:https://www.prnewswire.com/news-releases/the-automotive-relay-market-is-...

Key Points: 
  • The automotive relay market is projected to grow from USD 12.2 billion in 2022 to USD 15.5 billion by 2027, at a CAGR of 5.0% for the same period.
  • Additionally, the demand for premium vehicles in European and North American countries contributes to the demand for automotive relays.
  • The report also helps stakeholders understand the market’s pulse and provides information on key market drivers, restraints, challenges, and opportunities.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

Retrieved on: 
Monday, October 24, 2022
SAN, Streptococcus pneumoniae, Conference, IND, Infection, Infant, Private Securities Litigation Reform Act, Investigational New Drug, Program, Mortality, Meningitis, 20B, Sinusitis, Chemistry, Bacteria, Subclinical infection, Streptococcus, Antigen, Immunoglobulin G, Pneumonia, Immunization, Company, 23F, GLOBE, Genetically modified bacteria, FDA, Sutro Biopharma, PD, Review, Vaccine, OPA, Security (finance), Ageing, U.S. Securities and Exchange Commission, Vaccination, PCV, Host, Immunodeficiency, Otitis media, Disease, Peterborough, SEC, Webcast, Periodontal disease, IPD, VAX, Adult, Safety, Fast Track, 10A, Death, Public health, Pharmaceutical industry, Generic drug, COVID-19

-- Vaxcyte to Advance Potential Best-in-Class VAX-24 Clinical Program in Adult and Pediatric Populations --

Key Points: 
  • These four incremental serotypes cover 10-15 percent of strains causing invasive pneumococcal disease (IPD) over the current standard-of-care in adults.
  • We are thrilled with these positive topline results from our Phase 1/2 proof-of-concept study, which met all of our objectives.
  • The study results demonstrate that VAX-24 has the potential to provide broader coverage and better immune responses relative to the standard-of-care.
  • Topline safety, tolerability and immunogenicity data from the infant Phase 2 study primary 3-dose immunization series are expected by 2025.

Air Canada Marks its 85th Anniversary, Donates CF-TCC, Historic Aircraft From its Original Fleet to Winnipeg's Royal Aviation Museum of Western Canada

Retrieved on: 
Wednesday, September 7, 2022
Aircraft, Electra, TCC, TCA, Canadian Airways, Lockheed, Aviation, Museum, Royal Aviation Museum of Western Canada, Lockheed Electra, Collection, Volunteering, Department, Senior, Flight operations quality assurance, Pleiades, Atmosphere, Travel, Airway, Trans-Canada Air Lines, Air Canada, Atmosphere of Earth, Transport Canada, History, Expo 86, Lockheed Corporation, Winnipeg James Armstrong Richardson International Airport, 50 (number), 10A, Airline

MONTREAL, Sept. 7, 2022 /CNW Telbec/ - In celebration of its 85th anniversary, Air Canada today donated its historic aircraft, an original Lockheed L-10A Electra airplane to Winnipeg's Royal Aviation Museum of Western Canada.

Key Points: 
  • MONTREAL, Sept. 7, 2022 /CNW Telbec/ - In celebration of its 85th anniversary, Air Canada today donated its historic aircraft, an original Lockheed L-10A Electra airplane to Winnipeg's Royal Aviation Museum of Western Canada.
  • The aircraft, with registration CF-TCC, was one of three purchased by Air Canada's forerunner, Trans-Canada Air Lines (TCA), in 1937.
  • When not flying, the aircraft has been based in the Western Canada Aviation Museum in Winnipeg, Manitoba, or stored in Air Canada's Winnipeg hangar.
  • In 2022, on occasion of Air Canada's 85thanniversary, the airline's Lockheed 10A made its final journey to the Royal Aviation Museum of Western Canada in Winnipeg.

Pfizer announces PREVNAR 20™ (pneumococcal 20-valent conjugate vaccine) is now available in Canada for the prevention of pneumonia and invasive pneumococcal disease in adults 18 years of age and older

Retrieved on: 
Thursday, July 21, 2022
Death, Infection, Pleural empyema, CAP, Case fatality rate, Subclinical infection, IPD, Minister of Health (Canada), Twitter, 23F, PD, Streptococcus pneumoniae, Sepsis, Health, Risk, Health Canada, Adult, Foothills Medical Centre, Safety, Urinary tract infection, Cough, Community-acquired pneumonia, YouTube, Streptococcus, Disease, Science, LinkedIn, Vaccination, Sneeze, Meningitis, Conjugate vaccine, 10A, Vaccine, QC, Facebook, Pfizer, Pneumonia

"PREVNAR 20is significant in our ongoing fight against pneumococcal disease, including pneumonia in adults, and helps protect against disease-causing serotypes that cause potentially serious respiratory infections.

Key Points: 
  • "PREVNAR 20is significant in our ongoing fight against pneumococcal disease, including pneumonia in adults, and helps protect against disease-causing serotypes that cause potentially serious respiratory infections.
  • More than 6,000 adult subjects 18 years and older participated in the three Phase 3 trials, including adults 65 years of age and older, pneumococcal vaccine-nave adults, and adults with prior pneumococcal vaccination.
  • PREVNAR 20builds on Pfizer's legacy of more than two decades of experience in developing and supplying innovative pneumococcal conjugate vaccines.
  • To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on LinkedIn , Facebook , Twitter or YouTube .